Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company ImmunoPrecise Antibodies Ltd. (the Company ) 3204 4464 Markham Street, Victoria, British Columbia, V8Z 7X8, Canada Item 2
Friday, December 8, 2023 1 min read
Key Takeaway: MATERIAL CHANGE REPORT
Item 1 Name and Address of Company ImmunoPrecise Antibodies Ltd. (the Company ) 3204 4464 Markham Street, Victoria, British Columbia, V8Z 7X8, Canada Item 2 Date of Material Change December 8, 2023 Item 3 News Releases A news release with respect to the
Full Press Release Details
MATERIAL CHANGE REPORT
Item 1
Name and Address of Company
ImmunoPrecise Antibodies Ltd. (the Company ) 3204 4464 Markham Street, Victoria, British Columbia, V8Z 7X8, Canada
Item 2
Date of Material Change
December 8, 2023
Item 3
News Releases
A news release with respect to the material change was disseminated by the Company on December 8, 2023 through Business Wire and subsequently filed on SEDAR+.
Item 4
Summary of Material Change
On December 8, 2023, the Company completed its previously announced sale of an aggregate of 1,265,000 common shares of the Company (each, a " Common Share ") at a purchase price of US$1.00 per Common Share in an underwritten public offering (the " Offering ") priced at-the-market under the Nasdaq Capital Market (the " Nasdaq ") rules. The 1,265,000 Common Shares includes 165,000 Common Shares issued pursuant to the full exercise by an underwriter of its over-allotment option. The aggregate gross proceeds to the Company were approximately US$1.265 million, before the underwriters' discount and commissions for the facilitation of the Offering.
Item 5
Full Description of Material Changes:
On December 8, 2023, the Company completed its previously announced Offering of an aggregate of 1,265,000 Common Shares of the Company at a purchase price of US$1.00 per Common Share and priced at-the-market under the Nasdaq rules. The aggregate gross proceeds to the Company were approximately US$1.265 million, before the underwriter's discount and commissions for the facilitation of the Offering. The Benchmark Company acted as the sole book-running underwriter and R.F. Lafferty acted as co-underwriter for the Offering. The securities were offered and sold pursuant to a shelf Registration Statement on Form F-3 (File No. 333-273197) that was declared effective by the United States Securities and Exchange Commission (the " SEC ") on July 14, 2023. A copy of the final prospectus supplement and accompanying prospectus describing the terms of the offering has been filed with the SEC and is available on its website at www.sec.gov . No securities were offered or sold to Canadian purchasers.
Item 6
Reliance on Section 7.1(2) of National Instrument 51-102
Not applicable.
Item 7
Omitted Information
Not applicable.
Item 8
Executive Officer
Jennifer Bath Chief Executive Officer (250) 483-0308